Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
- PMID: 38137452
- PMCID: PMC10741005
- DOI: 10.3390/biomedicines11123231
Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
Abstract
Secreted protein acidic and rich in cysteine (SPARC) expression has been proposed as a prognostic and predictive biomarker for some cancer types, but knowledge about the predictive value of SPARC polymorphisms in the context of neoadjuvant therapy for breast cancer (BC) is lacking. In 132 HER2-negative BC patients treated with neoadjuvant chemotherapy, we determined polymorphisms in the SPARC gene and analyzed their association with outcome. We also determined SPARC protein expression in tumor tissue. SPARC rs19789707 was significantly associated with response to treatment according to the Miller and Payne system in the breast (multivariate: odds ratio (OR), 3.81; p = 0.028). This association was significant in the subgroup of patients with luminal tumors (univariate: p = 0.047). Regarding survival, two SPARC variants showed significant associations with event-free survival: the rs19789707 variant in the subgroup of luminal A tumors (univariate: p = 0.006), and the rs4958487 variant in the subgroup of luminal B tumors (univariate: p = 0.022). In addition, SPARC rs4958487, rs10065756, and rs12153644 were significantly correlated with SPARC protein expression. Our findings suggest that SPARC polymorphisms could be good predictors of treatment response and survival in BC patients treated with neoadjuvant chemotherapy, especially those with luminal tumors.
Keywords: SPARC; biomarker; breast cancer; neoadjuvant therapy; polymorphisms.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10741005/bin/biomedicines-11-03231-g001a.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10741005/bin/biomedicines-11-03231-g001a.gif)
Similar articles
-
Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis.PLoS One. 2013 Apr 26;8(4):e62451. doi: 10.1371/journal.pone.0062451. Print 2013. PLoS One. 2013. PMID: 23638089 Free PMC article.
-
The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy.Oncol Lett. 2020 Apr;19(4):2705-2712. doi: 10.3892/ol.2020.11354. Epub 2020 Jan 27. Oncol Lett. 2020. PMID: 32218821 Free PMC article.
-
Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.Cancer Chemother Pharmacol. 2019 Apr;83(4):639-647. doi: 10.1007/s00280-019-03769-7. Epub 2019 Jan 14. Cancer Chemother Pharmacol. 2019. PMID: 30643929
-
Prognostic Significance of SPARC Expression in Breast Cancer: A Meta-Analysis and Bioinformatics Analysis.Biomed Res Int. 2022 Feb 15;2022:8600419. doi: 10.1155/2022/8600419. eCollection 2022. Biomed Res Int. 2022. PMID: 35211625 Free PMC article. Review.
-
Prognostic role of SPARC expression in gastric cancer: a meta-analysis.Arch Med Sci. 2014 Oct 27;10(5):863-9. doi: 10.5114/aoms.2014.46207. Epub 2014 Oct 23. Arch Med Sci. 2014. PMID: 25395936 Free PMC article. Review.
References
-
- Bear H.D., Anderson S., Smith R.E., Geyer C.E., Mamounas E.P., Fisher B., Brown A.M., Robidoux A., Margolese R., Kahlenberg M.S., et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 2006;24:2019–2027. doi: 10.1200/JCO.2005.04.1665. - DOI - PubMed
-
- Buzdar A.U., Singletary S.E., Theriault R.L., Booser D.J., Valero V., Ibrahim N., Smith T.L., Asmar L., Frye D., Manuel N., et al. Prospective Evaluation of Paclitaxel versus Combination Chemotherapy with Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients with Operable Breast Cancer. J. Clin. Oncol. 1999;17:3412–3417. doi: 10.1200/JCO.1999.17.11.3412. - DOI - PubMed
-
- Liedtke C., Mazouni C., Hess K.R., André F., Tordai A., Mejia J.A., Symmans W.F., Gonzalez-Angulo A.M., Hennessy B., Green M., et al. Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer. J. Clin. Oncol. 2008;26:1275–1281. doi: 10.1200/JCO.2007.14.4147. - DOI - PubMed
-
- Untch M., Fasching P.A., Konecny G.E., Hasmüller S., Lebeau A., Kreienberg R., Camara O., Müller V., Du Bois A., Kuḧn T., et al. Pathologic Complete Response after Neoadjuvant Chemotherapy plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results from the TECHNO Trial of the AGO and GBG Study Groups. J. Clin. Oncol. 2011;29:3351–3357. doi: 10.1200/JCO.2010.31.4930. - DOI - PubMed
-
- Von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., Gerber B., Eiermann W., Hilfrich J., Huober J., et al. Definition and Impact of Pathologic Complete Response on Prognosis after Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J. Clin. Oncol. 2012;30:1796–1804. doi: 10.1200/JCO.2011.38.8595. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous